Some of these measures could take significant time to implement and others may require judicial or other third-party approval. Those remedial measures could include a potential corporate reorganization, restructuring or bankruptcy filing involving all or a portion of our business, asset sales or other divestitures, cost-saving initiatives, corporate realignments or strategic partnerships. The occurrence or possibility of any such result has caused us to engage, and may result in further engagement in strategic reviews that ultimately may result in our pursuing one or more significant corporate transactions or other remedial measures, including on a preventative or proactive basis. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, contingency planning and any potential restructuring the timing, impact or results of any pending or future litigation, investigations or claims or actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings our ability to satisfy judgments or settlements or pursue appeals including bonding requirements our ability to adjust to changing market conditions our ability to attract and retain key personnel our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness our ability to incur additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or general corporate or other purposes our ability to refinance our indebtedness a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs or repay indebtedness. All forward-looking statements in this press release reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this press release. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "future," "potential" or similar expressions are forward-looking statements. Learn more at connect with us on LinkedIn.Ĭautionary Note Regarding Forward-Looking StatementsĬertain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, any statements relating to the status or outcome of litigation or settlement discussions. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Endo cannot speculate on the likelihood, nature or timing of any outcome.Įndo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. At the same time, Endo is exploring other strategic alternatives, and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement. The Company is continuing to litigate opioid claims not covered by its settlements and to pursue settlements that it believes are in its best interests while remaining focused on its primary goal of achieving a global settlement. The plaintiffs in those cases agreed to sever Endo's subsidiaries from these upcoming trials pending implementation of the settlement. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. The Texas settlement resolves, among other things, claims against Endo's subsidiaries in two cases set for trial in Texas state court in 2022: County of Dallas v. The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims. The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Texas and its subdivisions in exchange for a total payment of $63 million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |